Consensus Lipocine Inc.

Stocks

LPCN

US53630X2036

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 19/09/2026 +04			5-day change	1st Jan Change
2.210 ^USD	-0.45%		-2.64%	-72.48%

09-14	Lipocine Initiates BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression	CI
08-22	Lipocine Inc. Announces Appointment of Michael Grissinger as Member of the Compensation Committee, Effective August 18, 2026	CI

Evolution of the Average Target: Lipocine Inc.

Evolution of the Target Price: Lipocine Inc.

Changes in Analyst Recommendations: Lipocine Inc.

ba8ae9b031.yW-JsudUYaQUmJhwfs4SOR5ZmRn6bonXq5rJ4GWJ9l8.jh_e_4sTJZdDwKoHTo1lQFIUyS7LHOKRyNWjlj_bxRuaKLrz0yUM6mH-wQ~01b2fe56ab700446eadfecc94fc52bf8

Analysts' recommendations: Lipocine Inc.

04-06	HC Wainwright Downgrades Lipocine to Neutral From Buy	MT
24/09/24	Alliance Global Partners Initiates Coverage on Lipocine With Buy Rating, $10 Price Target	MT
26/08/21	Lipocine : HC Wainwright Adjusts Lipocine's Price Target to $3.50 From $2.50, Keeps Buy Rating	MT
24/06/21	Lipocine : Cantor Fitzgerald Starts Lipocine at Overweight With $3 Price Target	MT
27/05/21	Lipocine : Ladenburg Thalmann Adjusts Lipocine's Price Target to $2.50 From $3, Maintains Buy Rating	MT
27/05/21	Lipocine : HC Wainwright Adjusts Price Target for Lipocine to $2.50 From $3, Maintains Buy Rating	MT
10/12/20	Lipocine : Ladenburg Thalmann Upgrades Lipocine to Buy From Neutral, $3 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	LIPOCINE INC.			-	-	+171.49%
	WUXI APPTEC CO., LTD.					+16.92%
	ARGENX SE					+17.91%
	WUXI BIOLOGICS (CAYMAN) INC.					+15.47%
	INSMED INCORPORATED					+66.29%
	BIONTECH SE					+23.62%
	GENMAB A/S					+8.57%
	PHARMAESSENTIA CORPORATION					+18.41%
	EXELIXIS, INC.					-8.01%
	SUMMIT THERAPEUTICS INC.					+62.99%
	Average					+39.37%
	Weighted average by Cap.					+22.84%

See all sector performances

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

OUTPERFORM

Number of Analysts

2

Last Close Price

2.210USD

Average target price

6.000USD

Spread / Average Target

+171.49%

High Price Target

6.000USD

Spread / Highest target

+171.49%

Low Price Target

6.000USD

Spread / Lowest Target

+171.49%

Analyst Consensus Detail

Consensus revision (last 18 months)

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

Stock Market
Stocks
LPCN Stock
Consensus Lipocine Inc.

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!